Purple Biotech (PPBT) Net Cash Flow (2017 - 2026)
Purple Biotech (PPBT) posted quarterly Net Cash Flow of -$3.1 million for Q1 2026, down 94.07% year-over-year from -$52.9 million in Q1 2025, and down 259.27% quarter-over-quarter from -$874000.0 in Q4 2025.
Purple Biotech (PPBT) Net Cash Flow (2017 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Net Cash Flow for 10 consecutive years, with -$3.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 94.07% year-over-year to -$3.1 million; the TTM figure through Mar 2026 stood at -$213000.0 (up 94.93% YoY), while the FY2025 annual figure was $1.3 million, up 118.48% from the prior year.
- Net Cash Flow declined to -$3.1 million in Q1 2026 per PPBT's latest filing, from -$874000.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $12.7 million in Q1 2022 and bottomed at -$9.4 million in Q2 2022.
- Historically, Net Cash Flow has averaged -$306882.4 across 5 years, with a median of -$1.1 million in 2024.
- On a YoY basis, Net Cash Flow climbed as much as 1565.66% in 2022 and fell as far as 3228.0% in 2022.
- Purple Biotech's Net Cash Flow stood at $3.9 million in 2022, then plunged by 117.09% to -$662000.0 in 2023, then surged by 396.53% to $2.0 million in 2024, then plunged by 144.52% to -$874000.0 in 2025, then slumped by 259.27% to -$3.1 million in 2026.
- Business Quant data shows PPBT's Net Cash Flow at -$3.1 million in Q1 2026, -$874000.0 in Q4 2025, and $4.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Purple Biotech | 133.62 | 133.62 | - | -384,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.14 Mn |
| Mar 31, 2026 | -3.14 Mn |
| Dec 31, 2025 | -874,000.00 |
| Dec 31, 2025 | -874,000.00 |
| Sep 30, 2025 | 4.87 Mn |
| Sep 30, 2025 | 4.87 Mn |
| Jun 30, 2025 | -1.07 Mn |
| Jun 30, 2025 | -1.07 Mn |
| Mar 31, 2025 | -1.62 Mn |
| Mar 31, 2025 | -1.62 Mn |
| Dec 31, 2024 | 1.96 Mn |
| Dec 31, 2024 | 1.96 Mn |
| Sep 30, 2024 | -1.09 Mn |
| Sep 30, 2024 | -1.09 Mn |
| Jun 30, 2024 | -3.46 Mn |
| Jun 30, 2024 | -3.46 Mn |
| Mar 31, 2024 | -4.50 Mn |
| Mar 31, 2024 | -4.50 Mn |
| Dec 31, 2023 | -662,000.00 |
| Dec 31, 2023 | -662,000.00 |